Skip to content

Depression research published in 2024

Page 6 of 26: studies 101 to 120 of 512, newest first. Back to the depression overview

Studies

Intervention Study on the Impact of Internet-Based Mindfulness Meditation on Depression and Anxiety among University Students

International Journal of Education and Humanities October 23, 2024 Qiuqiang Zheng, Weiwei Yang

This study explores the effectiveness of internet-based mindfulness meditation interventions in mitigating depression and anxiety symptoms among college students. A total of 72 participants were randomly assigned to one of three groups: offline mindfulness intervention, online mindfulness intervention, and a control group. The intervention lasted for eight weeks, during which participants'...

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.

Current Topics in Behavioral Neurosciences October 23, 2024 Grace Viljoen, Felix Betzler 5 citations

There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...

Systematic Review of the Effect of Psychedelic-Assisted Therapy on Attitudes Toward Death, Life, and Spirituality on Symptoms of Distress, Depression, and/or Anxiety in Patients with Life-Threatening Illness

Psychedelic Medicine October 15, 2024 Thivya Turner, Paul Glue 1 citation

Background: The underlying mechanism(s) of action of psychedelic-assisted therapy (PAT) to reduce distress, depression, and/or anxiety symptoms in life-threatening illness are poorly understood. It has been postulated that addressing death anxiety, and components of spiritual and existential distress, may be mediating factors. Method: This systematic review describes the current evidence base...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

An evaluation of the efficacy and side effects of a single dose of ketamine in major depressive disorder.

Postgraduate Medical Journal October 14, 2024 Betül Uyar, Mehmet Güneş 1 citation

This study aims to provide a comprehensive overview of the antidepressant and antisuicidal efficacy of ketamine in patients with unipolar depression, with a focus on the clinical evidence and safety profile. In our study, the data of 120 major depressive disorder patients who received single-dose ketamine infusion therapy were evaluated retrospectively, with Montgomery-Asberg Depression Rating...

DOI: 10.1093/postmj/qgae142 (opens in new tab) Full text (opens in new tab) Single dose Suicide Depression treatment Ketamine therapy +3

Long-Term Effects of Single and Repeated Ketamine Infusions on Treatment-Resistant Depression: A Retrospective Chart Review Study

Psychoactives October 12, 2024 Sofia Sakopoulos, Lisa D. Hinz 4 citations

Treatment-resistant depression (TRD) is a substantial public health burden with limited treatment options. Recent evidence suggests that single and repeated-dose ketamine infusions have rapid and significant antidepressant effects on individuals with TRD. Few studies have compared single or repeated (6) ketamine infusions past 14 days post-treatment. This retrospective chart review study...

Development of a mindfulness-based intervention for narcolepsy: a feasibility study.

Sleep October 11, 2024 Jennifer M Mundt, Phyllis C Zee, Matthew D Schuiling et al. 3 citations

Mindfulness-based interventions (MBI) have been shown to improve psychosocial functioning in medical populations but have not been studied in narcolepsy. This study examined the feasibility and acceptability of an MBI that was adapted for narcolepsy, including three variations in program length. Adults with narcolepsy (N = 60) were randomized to MBI groups of varying durations: brief (4 weeks),...

The Effect of a Mindfulness-Based Stress Reduction Program on Depression and Quality of Life in Cancer Patients: A Meta-Analysis Study.

Holistic Nursing Practice October 10, 2024 Esma Özmaya, Sevda Uzun, Tufan Aytaç

Mindfulness-based interventions have been receiving growing attention in cancer care. This study was performed to determine the effect of a mindfulness-based stress reduction program on depression and quality of life in cancer patients. The screenings in the study were performed in January to May 2023 through the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science,...

Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.

European Archives of Psychiatry and Clinical Neuroscience October 9, 2024 Jiafeng Li, Ling Ma, Huan Sun et al. 5 citations

The current systematic review and meta-analysis examined the effect of racemic ketamine or esketamine on suicidal ideation in individuals with uni- or bipolar depression. We searched the MEDLINE, Embase, Central, PsycINFO, and Web of Science databases to identify randomized controlled trials that examined the effect of racemic ketamine or esketamine monotherapy on suicidal ideation (SI) in...

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.

Biomedicines October 9, 2024 Piotr Kawczak, Igor Feszak, Tomasz Bączek 50 citations

Research over the past years has compared the enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine) of the previously known racemic mixture called ketamine (R/S-ketamine). Esketamine has been found to be more potent, offering three times stronger analgesic effects and 1.5 times greater anesthetic efficacy than arketamine. It provides smoother anesthesia with fewer side effects and...

Results of esketamine administration in a Greek population; A case series.

Psychiatriki October 8, 2024 Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis et al.

Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials...

DOI: 10.22365/jpsych.2024.006 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Fast-acting antidepressant Mood disorders Therapeutic intervention +5

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

The Journal of Clinical Psychiatry October 2, 2024 Mia C Santucci, Mina Ansari, Sina Nikayin et al. 12 citations

Background: Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression...

DOI: 10.4088/JCP.24m15376 (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar disorder Depression treatment Clinical trials +1

Correlation Status of Mindfulness with Depression, Anxiety, and Related Factors in Students of Khalkhal Faculty of Medical Sciences

Journal of Health and Hygiene October 1, 2024 Mehran Rostami Varnosfaderani, Feazeh Gharedaghi, Abdollah Asadi et al.

Background & objectives: Mindfulness, a psychological concept involving an individual's ability to focus on current experiences and regulate them, plays a crucial role in mental health.Depression and anxiety are prevalent issues among students, affecting their academic and psychological performance.Given the significance of mindfulness and its impact, this study aims to explore the correlation...

Nightmare frequency is a risk factor for suicidal ideation during the COVID-19 pandemic.

Journal of Sleep Research October 1, 2024 Courtney J Bolstad, Brigitte Holzinger, Serena Scarpelli et al.

The association between nightmare frequency (NMF) and suicidal ideation (SI) is well known, yet the impact of the COVID-19 pandemic on this relation is inconsistent. This study aimed to investigate changes in NMF, SI, and their association during the COVID-19 pandemic. Data were collected in 16 countries using a harmonised questionnaire. The sample included 9328 individuals (4848 women; age...

Efficacy of a Mind Space Application intervention on psychological outcomes in Thai university students with depression: A pilot randomized controlled trial.

Journal of Affective Disorders October 1, 2024 Chuntana Reangsing, Katemanee Moonpanane, Kanittha Pittchalard et al. 4 citations

This purpose of this study is to evaluate the effects of the Mind Space Application on psychological outcomes among Thai-university students with depression. Thai-university students with depression (N = 50) were recruited between November 2021 and January 2022. Participants were randomly assigned to either an 8-week mindfulness-based intervention via the Mind Space Application intervention or...

Mindfulness-based group intervention for adolescents with type 1 diabetes: initial findings from a pilot and feasibility randomized controlled trial.

Journal of pediatric psychology October 1, 2024 Molly Basch, Francesca Lupini, Sally Ho et al. 8 citations

To evaluate feasibility/acceptability of a virtual, group mindfulness-based intervention (MBI) adapted for pediatric type 1 diabetes (T1D). This two-way controlled trial randomized adolescents 1:1 to MBI (n = 20) or health education (HE; n = 22) groups lasting 6-7 weeks. Eligibility included 12-17 years, T1D ≥ 1 year, and elevated scores on PROMIS depression or anxiety measures. Recruitment,...

eMPower: An online Mind-body wellness Program for adults living with chronic health conditions: A three-armed randomized controlled trial protocol.

Contemporary Clinical Trials October 1, 2024 Emily K. Johnson, Kathleen Ismond, Ashley Hyde et al. 3 citations

Symptoms of depression and anxiety are prevalent among adults with chronic health conditions, contributing to reduced quality of life, morbidity, and mortality. Mind-body wellness interventions (i.e. psychology programming, mindful movement, breathwork, meditation) may impact mental health symptoms, with online delivery offering access and scalability. Whether online mind-body wellness...

Differential effects of repeated fluoxetine and ketamine administration on behavioral and pharmacological stressor-induced depression of digging behavior in mice.

Experimental and Clinical Psychopharmacology October 1, 2024 Kaitlyn J Partridge, Todd M. Hillhouse 1 citation

Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To...

DOI: 10.1037/pha0000711 (opens in new tab) Full text (opens in new tab) Antidepressants Stress response Personalized medicine Psychiatric treatment +1

Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Australian & New Zealand Journal of Psychiatry October 1, 2024 Alistair Carroll, Adam Bayes, Mark Montebello et al. 10 citations

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...

DOI: 10.1177/00048674241242315 (opens in new tab) Full text (opens in new tab) Drug dependence Regulations Ketamine therapy Mental health treatment +3

Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.

Psychiatry Research October 1, 2024 Je-Yeon Yun, Yong‐Ku Kim 11 citations

Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...